Immunotherapy for Small Cell Lung Cancer: Established Applications and Novel Approaches

Abstract: Small cell lung cancer (SCLC) is a devastating disease that has a case fatality rate of more than 90% despite best available treatments. As a […]

The Evolving Role of Immune Checkpoint Inhibitors in the Treatment of Triple-Negative Breast Cancer

Abstract: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer for which chemotherapy had been the only active treatment option once metastatic disease developed. […]

Immunotherapy for Mesothelioma: Rationale and New Approaches

Abstract: Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed […]

Emerging Role of Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer

Abstract: Non–small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC […]

Advances in the Development of Vaccines and Other Immunotherapies for Multiple Myeloma

H&O What types of immune-based therapies are in development for multiple myeloma? DA Immunotherapy is an important area in multiple myeloma, and this field encompasses […]

The Dawn of Immunotherapy for Breast Cancer

H&O Why have most of the efforts regarding immunotherapy in breast cancer been focused on triple-negative breast cancer? LE Triple-negative breast cancer (TNBC) is a […]

Immunotherapy in Colorectal Cancer With Mismatch Repair Deficiency

H&O Which immunotherapy agents have been approved for use in colorectal cancer (CRC) with mismatch repair deficiency (MMR-D)? MO We have a choice of 3 […]

Update on Perioperative Systemic Therapy for Urothelial Carcinoma

Abstract: Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint […]

Biomarkers for Immune Therapy in Gastrointestinal Cancers

Abstract: Immunotherapy with checkpoint blockade of pro-grammed death 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has substantially increased the number of anticancer agents in […]

Evolving Landscape of the Treatment of Metastatic Clear Cell Renal Cell Carcinoma

Abstract: The management of advanced clear cell renal cell carcinoma (RCC) has evolved over the past decade with the introduction of targeted therapies and immune […]

Immunotherapy in the Adjuvant Setting for High-Risk Melanoma

H&O Which patients with melanoma are at elevated risk for a recurrence after surgical resection? JW A patient at elevated risk is one whose 5-year […]

Does Adjuvant Therapy for High-Risk Melanoma With Either Immunotherapy or Targeted Therapy Affect Therapeutic Choices at Relapse?

H&O What are the main treatments used for adjuvant therapy in melanoma? MP The drugs that have received approval from the US Food and Drug […]

Immunotherapy in Colorectal Cancer

H&O Is colorectal cancer (CRC) a good target for immunotherapy? DL A subset of patients with CRC have tumors that are found to be deficient […]

The Promise of Immunotherapy in Anal Squamous Cell Carcinoma: A Novel Approach for an Orphan Disease

Abstract: An estimated 8200 men and women in the United States will receive a diagnosis of squamous cell carcinoma of the anal canal (SCCA) in […]

Immunotherapy in Ovarian Cancer: Where Are We Now, and Where Are We Going?

H&O What types of immunotherapy have been investigated for use in women with ovarian cancer? AJ The 3 broad areas of immunotherapy that have been […]

Emerging Treatments in Acute Myeloid Leukemia: Current Standards and Unmet Challenges

Abstract: Acute myeloid leukemia (AML) is rare and difficult to treat. Although remission is achieved in most patients with newly diagnosed disease, relapse occurs in […]

The Microbiome: A Basis for Novel Immunomodulation in Mice and Men

H&O Why does immunotherapy work better in some patients with melanoma than in others? HZ We are still unsure about that, but we are working […]

Immunotherapy in Urothelial Cancer, Part 2: Adjuvant, Neoadjuvant, and Adjunctive Treatment

Abstract: Urothelial cancer, which is predominantly seen in men, is common throughout the world. Most disease presents as non–muscle invasive bladder cancer (NMIBC), with cancer […]

Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease

Abstract: Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this […]

The Use of Immunotherapy in the First-Line Treatment of Lung Cancer

H&O How does immunotherapy in lung cancer work? NR There has been tremendous recent progress in the understanding of how immunotherapy works in lung cancer. […]